Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GALR1 | P47211 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655439 | 0.94 | TSHR (0.44) | TSHRGPR3CYP2A6MAOAMAOB | |
| SCHEMBL255956 | 0.94 | TSHR (0.44) | TSHRGPR3CYP2A6MAOAMAOB | |
| Methane SCHEMBL10428157 | 0.92 | TSHR (0.42) | TSHRCYP2A6MAOAMAOBCA1 | |
| Cyclopropane SCHEMBL2363143 | 0.92 | TSHR (0.42) | TSHRCYP2A6MAOAMAOBCA1 | |
| Cyclopropane SCHEMBL2363620 | 0.90 | TSHR (0.41) | TSHRCYP2A6MAOAMAOBCA1 | |
| SCHEMBL30533792 | 0.85 | CA1 (0.47) | TSHRGPR3CYP2A6CA1CA2 | |
| SCHEMBL61667 | 0.85 | CA1 (0.47) | TSHRGPR3CYP2A6CA1CA2 | |
| Methoxymethane SCHEMBL10859333 | 0.78 | CA2 (0.42) | GPR3MAOAMAOBCA1CA2 | |
| SCHEMBL9455245 | 0.76 | TSHR (0.62) | TSHRBCL2L1BADCYP2A6MAOA | |
| SCHEMBL3494049 | 0.72 | TSHR (0.50) | TSHRBCL2L1BADCYP2A6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1331225-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | G.D. SEARLE & CO. (US) | 2003-07-30 | — | — | EP | claimed |
| EP-1042314-B1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | SEARLE & CO (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020188119-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | LI JINGLIN (US) | 2002-12-12 | — | — | US | claimed |
| EP-1042314-A1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032478-A1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | G.D. SEARLE & CO. (US) | 1999-07-01 | — | — | WO | claimed |
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4424363-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| EP-4712959-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF | Mirum Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712959-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF | Mirum Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712959-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF | Mirum Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-2000001687-A1 | BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE & CO. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999032478-A1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | G.D. SEARLE & CO. (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0888333-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A9 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | — | 1998-02-26 | — | — | WO | disclosed |
| WO-1997033882-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE AND CO. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | TSHR 3834/4885GPR3 2485/4885BCL2L1 3770/4885 |
| US-20020188119-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | TST, THOP1, TH | TSHR 1463/4885GPR3 2193/4885BCL2L1 3986/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | TSHR 1651/4885GPR3 3171/4885BCL2L1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.